A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (BRIGHT 1012)

An Open-Label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Category & Conditions: Cancer

Medicine: DAURISMO TABLETS(GLASDEGIB)

ClinicalTrials.gov Identifier (NCT): NCT02367456

Protocol ID: B1371012

Print Download

Open Plain Language Summary Result: Click here